Advanced Filters
noise

neuropathy Clinical Trials

A listing of neuropathy medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found 428 clinical trials
D Delvys Rodríguez-Abreu, MD

Ozone Therapy in Chemotherapy-induced Peripheral Neuropathy: RCT (O3NPIQ)

The main objective of this clinical trial is to evaluate the effectiveness and cost-effectiveness of adding ozone therapy to the clinical management of patients with pain secondary to chemotherapy-induced peripheral neuropathy

18 - 100 years of age All Phase 2/3

Qutenza Versus Duloxetine in Chemotherapy-induced Peripheral Neuropathy (CIPN)

The primary objective is to determine whether in patients with CIPN pain, treatment with Qutenza has the same effect as treatment with duloxetine 60 mg daily.

18 years of age All Phase N/A
I Irene Cantarero-Villanueva, PhD

Preventing Chemotherapy-induced Peripheral Neuropathy Using PRESIONA Exercise Program

The aim of this study is to determinate if therapeutic exercise with blood flow restriction (BFR) during neoadjuvant chemotherapy potentialy neurotoxic could prevent the onset of chemotherapy induced peripheral neuropathy (CIPN) comparing to usual care.

18 - 70 years of age Female Phase N/A
A Alyssia Carlson

Omega-3 Fatty Acid Lipidomics in Diabetes Peripheral Neuropathy

Diabetic peripheral neuropathy (DPN) is the most common chronic complication of diabetes, affecting about 50% of patients with diabetes and leading to severe morbidity, poor quality of life, high mortality, and high health care costs. Due to the complex structure and anatomy of the peripheral nervous system, DPN presents with …

18 years of age All Phase 1/2
J J. A.C. Verbunt, MD, PhD

Chronic Pain Rehabilitation in Patients With Small Fiber Neuropathy

Small fiber neuropathy (SFN) is a condition that is dominated by invalidating neuropathic pain. Pharmacological neuropathic pain treatment is often disappointing, since pain reduction is mostly slight and side effects can be debilitating. Although neuropathic pain is caused by a lesion of the somatosensory system, also psychological factors, such as …

18 years of age All Phase N/A
M Manar Magdy Demonstrator at ain shams university

Effect of Melatonin in Patients With Diabetic Peripheral Neuropathy

The aim of the current study is to measure the effect of melatonin as adjunct therapy on oxidative stress, inflammatory markers and clinical outcome in type 2 diabetic patients with diabetic peripheral neuropathy.

40 - 75 years of age All Phase 2

Digital Heath Integration With Neuromodulation Therapies on Diabetic Neuropathy

This study will be carried out on 60 patients both gender male and female with diabetic neuropathy with age55-65 years. The patients will be selected from Elmahmoudia hospital .patients will be randomly assigned to two groups.

55 - 65 years of age All Phase N/A
M Mark Bussell, DPT, OCS

A Physiologic Comparison of Two Approaches to Treating Peripheral Neuropathy

Diabetic peripheral neuropathy is one of the most common and costly microvascular complications of diabetes impacting more than 50% of patients and costing more than 10.1 billion dollars annually. Intraneural Facilitation Therapy (INF® Therapy) is a non-invasive technique that has shown to improve balance and pain in patients with Type …

45 - 85 years of age All Phase N/A
B Bruce M Vrooman, MD

Low-Dose Naltrexone for the Treatment of Painful Diabetic Neuropathy

Diabetes affects more than 30 million people in the United States and is a leading cause of morbidity. Over 25% diabetics also suffer from debilitating painful diabetic neuropathy in the lower legs and feet. This pain can be severe, difficult to control, and have a significant negative impact on quality …

18 years of age All Phase 2
C Christina Brock, professor

Finerenone Treatment for Diabetic Cardiovascular Autonomic Neuropathy: the FibroCAN Study

Diabetic neuropathy is a serious and common complication of diabetes that currently has no cure. One form of this condition is cardiovascular autonomic neuropathy (CAN), which affects about 20% of people with diabetes-an estimated 100 million people worldwide. CAN is a significant risk factor for death and health problems like …

40 years of age All Phase 2

Simplify language using AI